期刊
JOVE-JOURNAL OF VISUALIZED EXPERIMENTS
卷 -, 期 84, 页码 -出版社
JOURNAL OF VISUALIZED EXPERIMENTS
DOI: 10.3791/51248
关键词
Medicine; Issue 84; Metastasis; circulating tumor cells (CTCs); CellSearch system; user defined marker characterization; in vivo; preclinical mouse model; clinical research
资金
- Ontario Institute of Cancer Research [08NOV230]
- Canada Foundation for Innovation [13199]
- Prostate Cancer Canada
- London Regional Cancer Program
- Frederick Banting and Charles Best Canada Graduate Scholarship Doctoral Award
- CIHR New Investigator Award
- Ontario Ministry of Research and Innovation
- John and Donna Bristol through the London Health Sciences Foundation
- Janssen Oncology
The majority of cancer-related deaths occur subsequent to the development of metastatic disease. This highly lethal disease stage is associated with the presence of circulating tumor cells (CTCs). These rare cells have been demonstrated to be of clinical significance in metastatic breast, prostate, and colorectal cancers. The current gold standard in clinical CTC detection and enumeration is the FDA-cleared CellSearch system (CSS). This manuscript outlines the standard protocol utilized by this platform as well as two additional adapted protocols that describe the detailed process of user-defined marker optimization for protein characterization of patient CTCs and a comparable protocol for CTC capture in very low volumes of blood, using standard CSS reagents, for studying in vivo preclinical mouse models of metastasis. In addition, differences in CTC quality between healthy donor blood spiked with cells from tissue culture versus patient blood samples are highlighted. Finally, several commonly discrepant items that can lead to CTC misclassification errors are outlined. Taken together, these protocols will provide a useful resource for users of this platform interested in preclinical and clinical research pertaining to metastasis and CTCs.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据